Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer that is resistant to testosterone-lowering treatments. Symptoms of mCRPC include: difficulty urinating, pain while passing urine, or blood in the urine, weight loss and shortness of breath. Hormonal therapies are used to treat CRPC such as abiraterone (Zytiga) with corticosteroids inhibit the chemical production of testosterone throughout the body. Zytiga is used in conjunction with prednisone, a powerful anti-inflammatory medication. Other treatments for CRPC include chemo and immunotherapies.
Market Dynamics
Market players are focused on raising awareness campaigns related to prostate cancer, which is expected to fuel growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, on June 17, 2021, patient organization ZERO and Bayer AG, a global life sciences company, collaborated to launch 'We're Not Gonna Take It', a national prostate cancer education program. The campaign encourages men to get screened for prostate cancer and to learn more about risk factors such as family history and elevated prostate-specific antigen (PSA) levels.
Moreover, market players are focusing on product launches and approvals to strengthen their position in the global castrate-resistant prostate cancer market. For instance, on July 30 2019, Bayer AG, a global enterprise, announced that the U.S. Food and Drug Administration (FDA) approved Nubeqa (darolutamide), for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
Furthermore, market players are focusing on research and development activities for the treatment of castrate-resistant prostate cancer, which is expected to drive growth of the global castrate-resistant prostate cancer market. For instance, on April 10 2021, Cardiff Oncology Inc., a clinical-stage biotechnology company in collaboration with scientists at the Massachusetts Institute of Technology's Center for Precision Cancer Medicine (MIT), announced that new gene signature and mechanistic analyses from its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, April, 2021.
Key features of the study:
- This report provides an in-depth analysis of global castrate-resistant prostate cancer market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global castrate-resistant prostate cancer market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global castrate-resistant prostate cancer market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global castrate-resistant prostate cancer market.
Detailed Segmentation:
- Global Castrate-resistant Prostate Cancer Market, By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Global Castrate-resistant Prostate Cancer Market, By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- Global Castrate-resistant Prostate Cancer Market, By Route of Administration:
- Global Castrate-resistant Prostate Cancer Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Castrate-resistant Prostate Cancer Market, By Region:
- North America
- By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Therapy Type:
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- By Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Sanofi*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Astellas Pharma Inc.
- Bayer AG
- Bristol Myers Squibb
- Merck Sharp & Dohme
- Novartis International AG
- Eli Lilly & Company
- AstraZeneca plc.
“*” marked represents similar segmentation in other categories in the respective section.
